These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [The lymphocyte transformation test using phytohemagglutinin, lepromin and M. leprae in lepromin-negative and positive leprosy: prognostic value compared with that of lepromin]. Pagnano PM; Bechelli LM; de Lima Filho EC Acta Leprol; 1982; (86-87):83-95. PubMed ID: 6816002 [No Abstract] [Full Text] [Related]
23. The response of the patient with leprosy toward Mycobacterium leprae injected with lepromin. A histopathologic study four hours after injection. Saúl A Int J Lepr Other Mycobact Dis; 1971; 39(2):300-7. PubMed ID: 4948077 [No Abstract] [Full Text] [Related]
24. Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli--a report of five cases. Bhatki WS; Chulawala RG; Bapat CV; Deo MG Int J Lepr Other Mycobact Dis; 1983 Dec; 51(4):466-72. PubMed ID: 6368413 [TBL] [Abstract][Full Text] [Related]
25. Delayed hypersensitivity skin reactions to lepromins prepared from M. leprae and selected cultivable mycobacteria. Investigations at the Victoria Hospital, Dichpalli. Hogerzeil LM; Prabhudass N Lepr India; 1978 Oct; 50(4):560-5. PubMed ID: 374874 [No Abstract] [Full Text] [Related]
26. A comparative study on the Mitsuda type response to antigens of chemoautotrophic nocardioform bacteria and to standard lepromin in leprosy patients. Chakrabarty AN; Dastidar SG; Chandra AK; Mukherjee M; Chaudhuri SK Acta Leprol; 1999; 11(3):105-12. PubMed ID: 10544723 [TBL] [Abstract][Full Text] [Related]
27. Susceptibility to leprosy may be conditioned by an interaction between the NRAMP1 promoter polymorphisms and the lepromin response. Ferreira FR; Goulart LR; Silva HD; Goulart IM Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):457-67. PubMed ID: 15755200 [TBL] [Abstract][Full Text] [Related]
29. Lepromin-induced suppressor cells in lepromatous leprosy. Nelson EE; Wong L; Uyemura K; Rea TH; Modlin RL Cell Immunol; 1987 Jan; 104(1):99-104. PubMed ID: 2948676 [TBL] [Abstract][Full Text] [Related]
30. Extended studies on subclinical infection in leprosy. Bharadwaj VP; Ramu G; Desikan KV; Katoch K Indian J Lepr; 1984; 56(4):807-12. PubMed ID: 6398341 [No Abstract] [Full Text] [Related]
31. Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons form Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma. Chaudhuri S; Hajra SK; Mukherjee A; Saha B; Mazumder B; Chattapadhya D; Saha K Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):182-9. PubMed ID: 9728450 [TBL] [Abstract][Full Text] [Related]
32. Lepromin retesting as a factor of lepromin test positivation. Azulay RD Int J Lepr Other Mycobact Dis; 1974; 42(4):428-30. PubMed ID: 4617721 [No Abstract] [Full Text] [Related]
33. Anti-Mycobacterium leprae antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. González-Abreu E; González-Segredo A; de la Cruz F Lepr Rev; 1984 Dec; 55(4):337-40. PubMed ID: 6396474 [No Abstract] [Full Text] [Related]
34. Interaction of TaqI polymorphism at exon 9 of the vitamin D receptor gene with the negative lepromin response may favor the occurrence of leprosy. Goulart LR; Ferreira FR; Goulart IM FEMS Immunol Med Microbiol; 2006 Oct; 48(1):91-8. PubMed ID: 16965356 [TBL] [Abstract][Full Text] [Related]
35. Variable lepromin response to Mycobacterium leprae in resistant armadillos. Job CK; Kirchheimer WF; Sanchez RM Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):347-53. PubMed ID: 6685696 [TBL] [Abstract][Full Text] [Related]
36. Two candidate antileprosy vaccines--current status of their development. Talwar GP; Fotedar A Int J Lepr Other Mycobact Dis; 1983 Dec; 51(4):550-2. PubMed ID: 6368418 [No Abstract] [Full Text] [Related]
37. Epidemiological studies in children of a low-endemic region, a high-endemic region, and dwellers of a leprosy colony: evaluation of anti-ND-BSA antibodies and lepromin response. Shah DH; Vartak RR; Naik SS; Dandekar SR; Ganapati R Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):539-46. PubMed ID: 7868951 [TBL] [Abstract][Full Text] [Related]
38. Analysis of T-cell and B-cell responses to recombinant M. leprae antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in M. leprae nonresponders. Thole JE; Janson AA; Kifle A; Howe RC; McLean K; Nurilygn A; Filley E; Shannon EJ; Bulla GJ; Hermans J Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):369-80. PubMed ID: 7594920 [TBL] [Abstract][Full Text] [Related]
39. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy. Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953 [TBL] [Abstract][Full Text] [Related]
40. Immunomodulation with corticosteroids and levamisole in leprosy as gauged by in vivo lepromin and in vitro CMI responses. Kundu SK; Hazra SK; Chaudhuri SK; Nandy A Indian J Lepr; 1985; 57(1):37-57. PubMed ID: 3839826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]